Drug development is becoming more complex, expensive, and time-consuming. This is creating greater demand for companies that help pharmaceutical and biotechnology firms discover, test, and manufacture new medicines.
Charles River Laboratories is one of the world’s leading contract research organizations (CROs). While the company experienced slower growth during 2025 due to reduced biotech funding and cautious pharmaceutical spending, its long-term outlook remains positive as research investments gradually recover.
2025 Performance Shows Stability Despite Market Pressure
Charles River reported 2025 revenue of USD 4.02 billion, slightly lower than USD 4.05 billion in 2024, representing a 0.9% decline.
Despite softer revenue, the company generated USD 512.3 million in non-GAAP net income and USD 10.28 in non-GAAP earnings per share, demonstrating resilient profitability during a difficult market environment.
The company’s largest business, Discovery & Safety Assessment (DSA), generated USD 2.40 billion in revenue, accounting for nearly 60% of total sales.
Forecast Points Toward Recovery in 2026
Management expects business conditions to improve during 2026 as pharmaceutical companies restart research programs and biotechnology funding becomes healthier.
The company forecasts reported revenue growth of up to 1.5% and expects non-GAAP EPS to increase by approximately 4% to 9%. Charles River also expects organic revenue growth to return during the second half of 2026, supported by stronger customer bookings and operational improvements.
Cost-saving initiatives, restructuring programs, and efficiency improvements are expected to further strengthen operating margins.
Government Research Funding Supports Long-Term Demand
Government investment remains one of the strongest drivers for preclinical research.
The U.S. National Institutes of Health (NIH) continues to receive an annual budget of roughly USD 48 billion, making it the world’s largest public biomedical research organization. Thousands of research grants support universities, biotechnology companies, and pharmaceutical innovation each year, creating consistent demand for laboratory research and safety testing services.
Growing public investment in cancer research, rare diseases, neuroscience, infectious diseases, and gene therapies is expected to benefit research partners like Charles River over the long term.
Curious about the insights top industry leaders use to stay ahead? Download your FREE customized sample today: https://www.towardshealthcare.com/download-sample/5341
Strategic Restructuring to Improve Profitability
Rather than focusing only on revenue growth, Charles River is reshaping its business portfolio.
The company announced the sale of selected underperforming businesses, including parts of its European drug discovery operations and certain manufacturing businesses.
These divestitures are expected to reduce annual revenue by more than USD 200 million, but management expects operating margins to improve by at least 100 basis points, making the company more efficient and profitable.
Growing Demand from Biopharmaceutical Innovation
The pharmaceutical industry continues to invest heavily in advanced medicines including cell therapy, gene therapy, biologics, and precision medicine.
Each new therapy requires laboratory research, toxicology studies, safety testing, regulatory support, and manufacturing services before reaching patients.
Charles River’s broad scientific capabilities position it to benefit as global drug pipelines continue expanding.
Key Financial Snapshot
| Indicator | Latest Figure |
|---|---|
| 2025 Revenue | USD 4.02 billion |
| 2024 Revenue | USD 4.05 billion |
| Revenue Change | -0.9% |
| Discovery & Safety Assessment Revenue | USD 2.40 billion |
| Non-GAAP Net Income | USD 512.3 million |
| Non-GAAP EPS (2025) | USD 10.28 |
| Expected EPS Growth (2026) | 4%–9% |
| Expected Revenue Growth (2026) | Flat to +1.5% |
| NIH Annual Budget | ~USD 48 billion |
Outlook Remains Positive
Although Charles River faced slower demand during 2025, the company enters 2026 with improving booking trends, stronger operational efficiency, and a streamlined business portfolio.
Continued government investment in biomedical research, rising pharmaceutical R&D spending, and increasing demand for outsourced drug development services are expected to support future growth. If management successfully executes its restructuring strategy while maintaining scientific leadership, Charles River Laboratories is well positioned to deliver stronger earnings and sustainable long-term value in the coming years.
Get a 360° view of the Pharma Market with our expert-designed platform. Discover valuable insights, statistical trends, country-specific data, and competitor strategies all in one place. Whether you’re planning a strategy, exploring investment opportunities, or benchmarking your position, the dashboard brings clarity and speed to every decision. Click to visit and access the dashboard, your complete market intelligence hub is ready.
Access the Dashboard: https://www.towardshealthcare.com/access-dashboard
About Us
Healthcare WebWire is a part of Towards Healthcare Research and Consulting provides strategic intelligence and research expertise across the pharmaceutical market, including branded drugs, generic medicines, biologics, biosimilars, specialty pharmaceuticals, OTC products, and drug delivery systems. We support pharmaceutical companies with market analysis, pipeline assessment, and competitive insights to help drive innovation, strengthen commercialization strategies, and capture emerging growth opportunities in the evolving healthcare landscape.
You can place an order or ask any questions, please feel free to contact us at [email protected]
Europe Region – +44 778 256 0738
North America Region – +1 8044 4193 44
APAC Region: +91 9356 9282 04
Visit Our Website: https://www.towardshealthcare.com
Find us on social platforms: LinkedIn | Twitter | Instagram | Medium